S. Jazayeri - Concepedia

Author

S. Jazayeri

Novartis (Switzerland)

Also Known As

Jazayeri, Sasha, S Sasha Jazayeri, S. Jazayeri, S. Sasha Jazayeri, S.N. Jazayeri, Sasha Jazayeri

Publications

545

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Novartis (China)Charles University Novartis (United States)Universität Hamburg

About

S. Jazayeri is an author at Novartis (Switzerland).

S. Jazayeri

Publications

532

Citations

H-Index

Page 1

	Year	Citations
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (<scp>JUNCTURE</scp>) C. Paul, J.‐P. Lacour, L. Tedremets, Journal of the European Academy of Dermatology and Venereology	2014	275
Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32‐week results from the randomized placebo‐controlled <scp>TRANSFIGURE</scp> trial Kristian Reich, John Sullivan, Petr Arenberger, British Journal of Dermatology	2018	98
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study* Kristian Reich, John Sullivan, Petr Arenberger, British Journal of Dermatology	2020	70
Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled <scp>JUNCTURE</scp> trial J.‐P. Lacour, C. Paul, S. Jazayeri, Journal of the European Academy of Dermatology and Venereology	2017	57
Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study Alan Menter, Petr Arenberger, Sigrid Balser, Expert Opinion on Biological Therapy	2020	20
FRI0460 Secukinumab Shows Significant Efficacy in Nail Psoriasis: Week 32 Results from The Transfigure Study Kristian Reich, John Sullivan, Petr Arenberger, Annals of the Rheumatic Diseases	2016	12

Page 1